Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $168.36 | 8 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valeant Pharmaceuticals North America LLC | $64.63 | 2 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $48.72 | 3 | $0 (2022) |
| Avanir Pharmaceuticals, Inc. | $40.02 | 2 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $14.99 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $14.99 | 1 | Bayer Healthcare Pharmaceuticals Inc. ($14.99) |
| 2022 | $20.46 | 1 | E.R. Squibb & Sons, L.L.C. ($20.46) |
| 2020 | $17.86 | 1 | E.R. Squibb & Sons, L.L.C. ($17.86) |
| 2019 | $40.02 | 2 | Avanir Pharmaceuticals, Inc. ($40.02) |
| 2017 | $75.03 | 3 | Valeant Pharmaceuticals North America LLC ($64.63) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Oncology | ||||||
| 02/09/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.46 | General |
| Category: Oncology | ||||||
| 08/18/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.86 | General |
| Category: Oncology | ||||||
| 07/18/2019 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 07/16/2019 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 11/28/2017 | Valeant Pharmaceuticals North America LLC | BIOTRUE (Device) | Food and Beverage | In-kind items and services | $30.28 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/06/2017 | Valeant Pharmaceuticals North America LLC | BIOTRUE ONE DAY (Device) | Food and Beverage | In-kind items and services | $34.35 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/20/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $10.40 | General |
| Category: Oncology | ||||||
About Dr. David Kahn, MD
Dr. David Kahn, MD is a Cognitive & Behavioral healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1679570311.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Kahn, MD has received a total of $168.36 in payments from pharmaceutical and medical device companies, with $14.99 received in 2023. These payments were reported across 8 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($168.36).
Practice Information
- Specialty Cognitive & Behavioral
- Other Specialties Behavioral Neurology & Neuropsychiatry, Psychiatry
- Location Providence, RI
- Active Since 07/07/2005
- Last Updated 05/19/2025
- Taxonomy Code 103TB0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1679570311
Products in Payments
- OPDIVO (Biological) $48.72
- NUEDEXTA (Drug) $40.02
- BIOTRUE ONE DAY (Device) $34.35
- BIOTRUE (Device) $30.28
- Nubeqa (Drug) $14.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cognitive & Behavioral Doctors in Providence
Dr. Jannette Rey, Ph.d, PH.D
Cognitive & Behavioral
Dr. Beth Bock, Phd, PHD
Cognitive & Behavioral
Dr. Gabriella Rothman, Ph.d, PH.D
Cognitive & Behavioral
Mrs. Nicole Groskreutz, Msed, Bcba, MSED, BCBA
Cognitive & Behavioral
Dr. Megan Kelly, Ph.d, PH.D
Cognitive & Behavioral
Dr. David Dove, Ph.d, PH.D
Cognitive & Behavioral